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der Universitaet Wuerzburg, Veisbacher Str. 7, Wuerzburg, GermanyReceived April 7, 2000; accepted April 7, 2000The discoveries of pathogenic human retroviruses in
the early 1980s have led to greatly increased interest in
anti-retroviral immune responses. Currently this interest
is especially keen because of the failure of more than a
decade of research to develop an effective human im-
munodeficiency virus (HIV) vaccine. Much of this vaccine
research has been empirical, but in the past few years
there has been an increased effort to take more rational
approaches based on stimulating the types of immune
responses that are expected to be protective. However, a
major stumbling block in this approach is the lack of
knowledge regarding which types of immune responses
are required for protection from retroviral infections.
Moreover, it has been speculated that protective immu-
nity against HIV may never be achieved given that strong
cellular and humoral immune responses are generated
during HIV infection, yet they fail to prevent AIDS. How-
ever, this view ignores what is known about immunolog-
ical memory and anamnestic immune responses. The
failure of a primary immune response to control an in-
fection does not preclude protection by immune re-
sponses that have been previously primed by vaccina-
tion. Of course, the HIV situation is fraught with compli-
cations such as its ability to evade neutralization by
antibodies (Parren et al., 1999). The presence of a stand-
ng titer of virus-neutralizing antibody is likely to be a
ritical aspect of long-term vaccine protection because
ntibodies have the ability to neutralize free virus with no
equirements for antigen presentation, cell activation, or
ell proliferation. Thus, antibodies can reduce the initial
irus challenge dose allowing time for the cellular im-
une system to convert from memory status to effector
tatus. Although some progress has been made1 To whom correspondence should be addressed. Fax: (406) 363-
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244(LaCasse et al., 1999), no vaccine strategies have yet
been designed which elicit broad-spectrum neutralizing
antibody responses in humans. To circumvent the anti-
body problems, vaccines have been designed which
specifically elicit T cell responses, in particular cytolytic
T lymphocyte (CTL) responses. However, it remains
questionable whether a CTL-based vaccine can be pro-
tective against retroviral infections, an issue that is ad-
dressed in this minireview.
Several approaches have been taken to determine the
types of immunological responses required for an effec-
tive retroviral vaccine, and each of these approaches has
certain limitations. One approach has been to study
immune responses in HIV-infected patients who usually
progress to AIDS and to compare them with responses
in “long-term nonprogressors” or “exposed but unin-
fected” patients. While this approach has yielded ex-
tremely valuable information, it is limited by being a
comparative study where experimentation is not possi-
ble. The most widely used model for experimentation is
nonhuman primates infected with simian immunodefi-
ciency virus (SIV), a virus closely related to HIV. Although
this is the best model for evaluating the potential of
candidate vaccines against HIV, it remains difficult to
determine immunological mechanisms of protection
against retroviruses in macaques. Problems with this
model include the limited number of available monkeys,
the genetic heterogeneity of the available animals, the
lack of certain immunological reagents, and ethical con-
siderations. We have taken a third approach, which is to
study mice infected with a murine leukemia virus known
as Friend virus (FV). The advantages of this model in-
clude the ability to work in genetically defined mouse
strains including congenic, transgenic, and knockout an-
imals, as well as the availability of a wide variety of
immunological reagents. An obvious drawback to the FV
model is that it is a different virus than HIV and the model
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245MINIREVIEWis not useful for studying HIV pathology or other virus-
specific aspects of infection. On the other hand, many
features of FV infections and the resultant immune re-
sponses are analogous to HIV infections in humans, so
the mouse model provides an opportunity to define fun-
damental concepts regarding immunity to retroviral in-
fection, some of which may be generally applicable.
The kinetics of virus replication and the development
of immune responses during FV infection of high recov-
ery (B10 3 A.BY)F1 mice are illustrated in Fig. 1. This
mouse strain is of special interest because of its ability
to recover from acute FV infection. Similar to HIV infec-
tions, virus titers peak quite rapidly in the acute phase,
but then also drop off quite rapidly as immune responses
develop and gain control over the infection. In HIV, the
fact that CTL responses rather than antibody responses
precede the drop in viremia has been cited as evidence
that antibodies do not play a role in early virus control.
Similar kinetics are seen in FV infections, but experimen-
tal evidence has shown that FV viremia cannot be con-
trolled in the absence of the antibody response (Britt and
Chesebro, 1983; Chesebro and Wehrly, 1979; Hasenkrug
et al., 1995). Thus, the lack of a temporal association
between antibody responses and virus loads is not nec-
essarily proof that these effectors play no role in virus
control. As will be discussed in more detail below, re-
covery from acute FV infection requires all three major
lymphocyte subsets: CD41 T cells, CD81 T cells, and B
ells (see Fig. 2).
FIG. 1. Schematic diagram of relative levels of virus versus levels o
.BY)F1 mice peaks at about day 10 while FV-induced splenomegaly
esponse is maintained for life while the T cell responses appear muc
bout 5% of chronically infected mice.Despite recovery from acute viremia, virus is never
ompletely cleared in (B10 3 A.BY)F1 mice, and they
cemain persistently infected at low levels for life. B cells
re the main reservoir for persistent FV (Hasenkrug et al.,
998), yet persistent FV infections are associated with
uppressed CD81 T cell responses. In HIV infections as
well, the immune system fails to completely eradicate
virus, and the host remains persistently infected for life.
Resting CD41 T cells are the main reservoir for persis-
tent HIV infection, but CD81 T cell responses also be-
come impaired (Brander and Walker, 1999). For both FV
and HIV infection the mechanisms by which CD81 T cell
esponses are suppressed are not yet understood, but
D41 T cells appear to be indirectly involved.
After an extended incubation period, persistent (un-
reated) HIV infections result in depletion of CD41 T cell
umbers to levels insufficient to mount effective immune
esponses. This depletion of CD41 T cells invariably
esults in the loss of control of HIV replication, develop-
ent of opportunistic infections, and/or increases in the
ncidence of certain cancers associated with the onset of
IDS. By contrast, CD41 T cells are not a prominent
reservoir for persistent FV and no depletion of CD41 T
cells occurs. Only about 5% of mice persistently infected
with FV die prematurely, typically from FV-induced leuke-
mias of erythroid or granulocytic origins (Chesebro et al.,
1979). However, if persistently infected mice are experi-
mentally depleted of CD41 T cells, virus is reactivated
nd FV-induced erythroleukemia develops in about 50%
f the mice (see Fig. 1) (Hasenkrug et al., 1998). Thus,
ike HIV, control of persistent FV infections involves a
1
ne effectors in unvaccinated, high recovery mice. Viremia in (B10 3
at about 2 to 4 weeks postinfection. The virus-neutralizing antibody
transient. Persistent virus reactivates and causes erythroleukemia inf immu
peaksritical role for CD4 T cells.
The next few paragraphs briefly summarize some of
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246 MINIREVIEWthe main aspects of T cells responses to the acute phase
of infection with FV. These responses mediate recovery
from viremia and splenomegaly.
CD41 T cell responses to FV infection are strongly
nfluenced by major histocompatibility complex (MHC or
-2 in the mouse) genes. Both H-2A and H-2E class II
ene products are known to influence CD41 T cell re-
sponses [see Hasenkrug and Chesebro (1997) for re-
view]. Peptides derived from FV envelope have been
shown to bind to these MHC class II molecules and to
act as cognate antigens for recognition by CD41 T cells
Iwashiro et al., 1993). Surprisingly, the kinetics of devel-
opment of FV-specific CD41 T cell responses are influ-
nced by an MHC class I gene, H-2D. This is unusual
ecause MHC class I genes typically influence CD81 T
cells and not CD41 T cells. The mechanism by which
-2D affects CD41 T cell responses is not completely
nderstood, but recent experiments have suggested that
roduction of IFN-g by CD81 T cells may be involved
Peterson et al., 2000). IFN-g production by CD81 T cells
ight help drive the CD4 response toward a protective
h1-type response as opposed to a nonprotective Th2-
ype response.
The importance of the CD41 T cell response to FV
nfection has been demonstrated in experiments using
1
FIG. 2. Effect of MHC on recovery from FV infection in unvaccinated
T cells, CD81 T cells, and B cells. The responses of these cells are reg
ut also their kinetics. MHC genes also regulate the degree of FV-ind
ression.ice depleted of CD4 T cells by monoclonal antibody
reatments and also in experiments with CD4 knockout
tice. Mice of the H-2b MHC type such as the (B10 3
A.BY)F1 strain described above mount effective immune
responses to FV infection and recover within a few
weeks from acute viremia and FV-induced splenomegaly.
However, if such mice are depleted of CD41 T cells
during acute infection, they fail to recover and develop
lethal FV-induced erythroleukemia (Robertson et al.,
1992). Even C57BL/6 mice which are highly resistant to
FV infections because of two genetic resistance factors,
H-2b (Chesebro et al., 1974) and Fv2 (Persons et al.,
1999), become highly susceptible if the CD4 locus has
been genetically inactivated (Hasenkrug, 1999).
What functions are provided by CD41 T cells that are
ssential for recovery from FV infection? First, immuno-
ogical help for the B cell response is extremely impor-
ant. Virus-neutralizing antibodies are necessary for re-
overy from acute FV infection (Chesebro and Wehrly,
979; Hasenkrug et al., 1995), and both IgM and IgG
irus-neutralizing antibody responses are CD41 T cell-
ependent (Super et al., 1998). Second, the CTL re-
ponse is critical for recovery, and studies indicate that
he CTL response to FV is at least partly dependent on
D41 T cells (Dittmer et al., 1999b; Hasenkrug et al.,
1995). Finally, CD41 T cells provide direct antiviral activ-
ties in certain circumstances, particularly during persis-
1
The recovery of mice such as (B10 3 A.BY)F1 is dependent on CD41
by MHC genes which control not only the specificity of the responses,
munosuppression, but all strains exhibit some signs of immunosup-mice.
ulatedent infection. The requirement for CD4 T cells in the
control of persistent FV does not appear to be related to
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(Hasenkrug et al., 1998). Recent experiments suggest
that secretion of IFN-g and direct cytolysis of infected
ells by CD41 T cells may be involved in the control of
persistent FV (unpublished results).
MHC class I genes strongly affect recovery from FV
infection. This effect is unusual in that the high recovery
phenotype is a recessive rather than a dominant trait as
has been found for other class I-restricted responses.
Homozygous H-2Db/b mice recover from high doses of FV,
hile H-2Db/d heterozygotes recover only from low doses,
and H-2Dd/d mice do not recover (Chesebro et al., 1990).
single point mutation in the H-2Db gene, such as the
bm14 mutation, is sufficient to convert mice from high
recovery to low recovery status (Miyazawa et al., 1992).
he requirement for homozygosity is not related to levels
f H-2Db expression (Hasenkrug et al., 1994) nor to the
ability of mice to present antigen in the context of Db
molecules (Chesebro et al., 1990), nor does the H-Dd
allele exert a negative influence as a transgene in the
context of an H-2b/b genetic background (Miyazawa et al.,
1992). Thus, it remains unclear why H-2b/b homozygosity
s advantageous for recovery.
Two FV antigens which bind to H-2Db molecules have
een described at the peptide level, one derived from
nvelope (Ruan and Lilly, 1991) and one from glycogag
Chen et al., 1996; Uenishi et al., 1998). Glycogag is a
FIG. 3. Adoptive transfer experiments show that all three major lym
transfers of immune spleen cells, (B10 3 A/Wy)F1 mice were challe
ransferred with purified lymphocytes remixed following the purificati
ubsets gave results similar to those obtained with transfers of CD81glycosylated form of the FV gag protein which is tran-
scribed via an alternative start site and is expressed on
c
tthe surface of infected cells. In our laboratory, CTL from
mice infected with FV do not react with the envelope
peptide, but show reactivity against the glycogag pep-
tide. FV has mutated sequences in and around the CTL
epitopes described for the related murine leukemia vi-
ruses AKV and Moloney (Beekman et al., 2000; Ossen-
dorp et al., 1996). These mutations alter processing of the
peptide epitopes and allow escape from recognition by
CTL specific for the Moloney and AKV viruses.
Mice recovering from FV infection show peak CTL
activity against FV at 2 to 3 weeks postinfection. If the
mice are depleted of CD81 T cells by monoclonal anti-
ody treatments they fail to recover from infection (Rob-
rtson et al., 1992). The importance of CTL in recovery is
also evident from the susceptibility of highly resistant
C57BL/6 mice in which the b2-microglobulin or CD8 gene
has been inactivated (Hasenkrug, 1999).
To study the role of T cells in vaccine protection,
mouse strains such as (B10.A 3 A/Wy)F1 which fail to
recover from acute infection were used. Vaccination of
such mice using live attenuated FV results in protection
from lethal FV challenge (Dittmer et al., 1998) and from
establishment of persistent infection (Dittmer et al.,
1999a). Studies have shown that CD41 T cells, CD81 T
ells, and B cells in vaccinated mice are very quickly
ctivated following virus challenge (Dittmer et al., 1999c)
nd that protection is abolished if mice are depleted of T
te subsets are necessary for vaccine protection. Following adoptive
ith a high dose of FV. Control mice (at the bottom) were adoptively
edures. Results of transfers of all dual combinations of lymphocyte
alone (Dittmer et al., 1999b).phocy
nged wells prior to vaccination. Thus, T cells are vital for pro-
ective immunization (Dittmer et al., 1999c).
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248 MINIREVIEWTo determine more precisely which immune lympho-
cytes were necessary for protective immunity, spleen
cells from immunized mice were separated according to
lymphocyte subset markers using immunomagnetic
beads, and the purified subsets were adoptively trans-
ferred into naive mice (Fig. 3). Results from virus chal-
lenge experiments indicated that B cells and both CD41
and CD81 T cell subsets were required to transfer com-
plete immune protection defined as protection from
acute viremia, splenomegaly, and the establishment of
persistent infection (Dittmer et al., 1999b). Adoptive trans-
fers of purified CD81 T cells alone achieved limited
protection: the mice became splenomegalic, but then
recovered. In addition, the CD81 T cell transfers did not
rotect against establishment of persistent infection (Fig.
). Protection by transfer of immune CD81 T cells could
be improved by increasing the numbers of transferred
cells such that splenomegaly was completely prevented.
However, even high numbers of immune CD81 T cells
ere not able to prevent the establishment of persistent
nfections (Dittmer and Hasenkrug, 2000). Furthermore,
he limited protection afforded by transfers of high num-
ers of immune CD81 T cells was dependent on endog-
enous CD41 T cells in the host as animals depleted of
CD41 T cells prior to adoptive transfer with high numbers
of CD81 T cells showed no protection from FV-induced
isease. In contrast, transfers of even high numbers of
D41 T cells alone provided no protection, suggesting
that their primary function was the provision of immuno-
logical help to CD81 T cells and B cells rather than direct
ntiviral activity. A study using a virus closely related to
V (Rauscher virus) also found that CD81 T cells required
CD41 T cells for transfer of immune protection (Hom et
l., 1991).
These adoptive transfer experiments illustrate several
mportant points. Immune CD81 T cells are potent effec-
tors that can prevent acute FV-induced disease in the
absence of any other immunological memory. However,
the dependence of immune CD81 T cells on host-derived
CD41 T cells indicates that either the in vivo expansion of
CD81 T cell numbers or their conversion from a memory
status to an effector status requires immunological help.
Furthermore, the inability of immune CD81 T cells alone
o prevent persistent infection illustrates an inherent
eakness in CTL-based immunity. CTL efficiently de-
troy infected cells but cannot eliminate free virus. Since
etroviruses rapidly establish persistence through infec-
ion of certain cell types, the chances of preventing
ersistence are greatly increased if multiple arms of
mmunity are brought to bear which quickly control both
ree virus and cell to cell spread of infection. Thus, both
TL and antibody perform functions essential for full
mmune protection, and both responses rely on immu-
ological help from CD41 T cells.There is little reason to believe that the immune re-
sponses required for protection against HIV will be lesscomplex than those required for protection from FV. In
fact, recent studies in HIV-infected patients and SIV-
infected macaques have revealed that the important im-
mune responses against immunodeficiency viruses and
FV may be very similar. Two experiments using SIV-
infected monkeys showed that CTL are able to suppress
immunodeficiency virus replication in vivo (Schmitz,
1999; Jin, 1999). The importance of CD4 cells in the
control of HIV replication has also been demonstrated in
a recent paper (Rosenberg et al., 1997). These CD4 cells
probably provide important help for anti-HIV CTL re-
sponses (Kalams et al., 1999). In addition, it has been
suggested that specific CD4 cells might have direct an-
tiviral activity against immunodeficiency viruses (Dittmer
and Hunsmann, 1997; Furci et al., 1997). Although the
role of antibodies in controlling HIV and SIV remains
controversial, some results have indicated that antibod-
ies play a significant role in restricting virus spread and
disease progression (Haigwood et al., 1996; Michael et
al., 1997). Thus, as in FV-infected mice, multiple compo-
nents of the immune response are likely important in the
control of HIV and SIV replication and spread. A major
implication of the FV research is that the requirements
for B cells, CD41 T cells, and CD81 T cells in protection
ay represent the minimal requirements for protection
gainst viruses such as HIV. If true, then the focus of HIV
accine research should shift from determining whether
ingle arms of immunity can provide protection to deter-
ining the best ways of eliciting the widest spectrum of
mmune responses possible.
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